Cost-Effectiveness of Cobas® EGFR Mutation Test Versus Sanger Sequencing in the Treatment of Locally Advanced or Metastatic NSCLC- A Payer Perspective in the United Kingdom
Abstract
Authors
A. Towse M. Gavaghan T. Strunz-McKendry S. Garfield N. Poulios